Grant: Operating Grant: COVID-19 - Project Grant
University of Toronto
$229,500.00
Targeting the novel coronavirus SARS-CoV-2 using an ancient antibody system
FY 2020-21
Summary
Antibodies are key molecules generated by cells of the immune system involved in the defense against invading pathogens. They are able to bind their targets with a very high degree of specificity. This specific target recognition makes antibodies also valuable reagents in biomedical research as well as in clinical diagnostic and therapeutic applications. While the immune system is capable of generating a vast variety of antibodies, certain targets are difficult to engage either because the protein architecture prevents binding to the target or because the immune system fails to respond to the target. To address this challenge, we propose to harness the variable lymphocyte receptor (VLR) antibody system of the evolutionarily distant jawless sea lamprey.
Similar to conventional antibodies, VLR antibodies recognize targets with a high degree of specificity. However, their protein architecture is radically distinct, suggesting that they may detect targets that cannot be recognized by conventional antibodies, a hypothesis supported by studies in our laboratory. We developed an approach to generate specific VLR antibodies. Here we propose to use VLR antibodies to specifically target SARS-CoV-2, the viral pathogen causing Covid-19. Our research will provide a new approach to target the virus, to devise a new class of diagnostic reagent an to explore new vulnerabilities of the viral pathogen.
Department
Program
Operating Grant: COVID-19 - Project Grant
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
442972
Name
Ehrhardt Rudolf A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Population and Public Health
Theme2
Biomedical
Prcname2
Special Cases
Projecttitle
Targeting the novel coronavirus SARS-CoV-2 using an ancient antibody system
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$229,500
Cihrequipment2
$0
Programname2
Operating Grant: COVID-19 - Project Grant
Keyworddelim
Diagnostic; Evolution; Monoclonal Antibody; Neutralizing Epitope; Posttranslational Modification; S-Protein; Variable Lymphocyte Receptor (Vlr)
Abstract
Antibodies are key molecules generated by cells of the immune system involved in the defense against invading pathogens. They are able to bind their targets with a very high degree of specificity. This specific target recognition makes antibodies also valuable reagents in biomedical research as well as in clinical diagnostic and therapeutic applications. While the immune system is capable of generating a vast variety of antibodies, certain targets are difficult to engage either because the protein architecture prevents binding to the target or because the immune system fails to respond to the target. To address this challenge, we propose to harness the variable lymphocyte receptor (VLR) antibody system of the evolutionarily distant jawless sea lamprey.
Similar to conventional antibodies, VLR antibodies recognize targets with a high degree of specificity. However, their protein architecture is radically distinct, suggesting that they may detect targets that cannot be recognized by conventional antibodies, a hypothesis supported by studies in our laboratory. We developed an approach to generate specific VLR antibodies. Here we propose to use VLR antibodies to specifically target SARS-CoV-2, the viral pathogen causing Covid-19. Our research will provide a new approach to target the virus, to devise a new class of diagnostic reagent an to explore new vulnerabilities of the viral pathogen.
Competitiondate
202011
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Ehrhardt, Rudolf A
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $229,500~ $0~